Insulin resistance: how insulin sensitivity is understood to work

What insulin is and the signal it carries

Insulin is a peptide hormone produced by the beta cells of the pancreas, in clusters of tissue called the islets of Langerhans. Its release is driven largely by rising blood glucose: when nutrients from a meal enter the bloodstream, the pancreas is understood to secrete insulin as a chemical signal announcing that fuel has arrived. This article is educational only and is not medical advice; it describes how a normal signaling pathway is understood to work and what researchers mean when that signal becomes less effective.

That signal is addressed to several tissues at once. Skeletal muscle is understood to be the largest site of insulin-stimulated glucose uptake, the liver is where insulin acts to reduce the glucose the organ releases, and fat (adipose) tissue takes up glucose and adjusts how it stores and releases energy. In broad terms, insulin is understood to shift the body from a fuel-releasing state toward a fuel-storing one — promoting the storage of glucose as glycogen and restraining the breakdown of stored fat.

The word that sits at the center of this topic is 'sensitivity.' In physiology, insulin sensitivity describes how strongly a tissue responds to a given amount of insulin. To understand what researchers mean by insulin resistance — a reduced response to that same signal — it helps first to follow the normal signal from the receptor on the cell surface to the moment glucose actually enters the cell.

How insulin tells a cell to take up glucose

Insulin does not enter the cells it acts on. Instead it binds to the insulin receptor, a protein that spans the cell membrane and belongs to a family called receptor tyrosine kinases. The receptor has an outer portion that binds insulin and an inner portion with enzyme activity. When insulin attaches to the outer subunits, the receptor is understood to change shape and switch on its inner kinase, which adds phosphate groups to itself — a step called autophosphorylation that begins the signal inside the cell.

From there the message passes through a relay of intracellular proteins. The activated receptor is understood to phosphorylate a family of docking proteins known as insulin receptor substrates (IRS). These in turn activate an enzyme called PI3-kinase (PI3K), which activates a kinase called Akt, also written PKB. This PI3K–Akt branch is the arm of insulin signaling most closely associated with the hormone's effects on glucose, and researchers describe it as a cascade in which each step switches on the next.

In muscle and fat cells, the payoff of that cascade is the movement of a glucose transporter called GLUT4. Under low-insulin conditions, GLUT4 is held inside the cell in storage vesicles. When the insulin signal reaches Akt, those vesicles are understood to move to the cell surface and fuse with the membrane, inserting GLUT4 channels through which glucose can flow into the cell along its concentration gradient. When insulin falls, GLUT4 is understood to be recycled back inside, and uptake slows. In the liver, the same signaling is understood to suppress the production of new glucose and encourage its storage as glycogen. Together these actions describe how insulin lowers blood glucose after a meal.

What researchers mean by insulin sensitivity and resistance

With the normal signal in view, insulin sensitivity can be defined more precisely: it is a measure of how much biological effect a given amount of insulin produces — how much glucose a tissue takes up, or how much the liver reduces its glucose output, per unit of insulin. A highly sensitive tissue responds strongly to a small amount. Insulin resistance is understood as the opposite condition: the tissues respond less, so the same amount of insulin produces a smaller effect.

A key part of what researchers describe is how the body is understood to compensate. When tissues respond less, the pancreas is understood to secrete more insulin to achieve the same control over blood glucose — a state of raised insulin levels sometimes called compensatory hyperinsulinemia. For a time, blood glucose can remain in a normal range precisely because insulin has risen to offset the weaker response. Researchers describe insulin resistance as a continuum rather than an on-off switch, and note that different tissues can be affected to different degrees.

It is worth being precise about what these terms are. Insulin sensitivity and insulin resistance describe a physiological state that researchers study and measure; they are not, by themselves, a diagnosis, and this article makes no claim about any individual. Insulin resistance is studied in the context of conditions such as metabolic syndrome and type 2 diabetes, but whether it is present, and what it means for a given person, is a clinical assessment for a licensed provider rather than something a general explainer can determine.

Where the signal is understood to weaken

When researchers ask where the insulin signal weakens, the answer they describe is usually not the receptor alone but the steps downstream of it — what is often called a post-receptor defect. A recurring theme in the literature is that the IRS docking proteins can be modified in a way that dampens the signal: instead of the activating tyrosine phosphorylation described earlier, they can undergo serine or threonine phosphorylation, which is understood to blunt the relay to PI3K and Akt and, in turn, to reduce GLUT4 movement to the cell surface.

Several biological factors are studied as contributors to that dampening. One is the accumulation of fat in tissues not designed to store much of it — so-called ectopic fat in muscle and liver — where lipid intermediates such as diacylglycerol and ceramides are studied as molecules that interfere with insulin signaling. Another is chronic low-grade inflammation: signaling molecules released by adipose tissue, including cytokines, are studied for their role in interrupting the same pathway. These are described as overlapping influences on a shared signaling route rather than a single cause.

An important caveat runs through all of this. The mechanisms of insulin resistance are an area of active research, and while the broad outline — a weakened post-receptor signal with reduced GLUT4 translocation — is widely described, the details and their relative importance remain under study, and a single unified explanation is still lacking. This section describes what has been proposed and investigated, not a settled account, and certainly not a statement about any particular person.

How insulin sensitivity is studied and measured

Because insulin sensitivity is a matter of degree, researchers have developed ways to estimate it. Some rely on simple fasting measurements: a blood sample for glucose and insulin can be combined in an index such as HOMA-IR, which uses the relationship between fasting glucose and fasting insulin as an approximation of how the two are balanced. Indices like these are convenient, which is why they appear often in research, though they are estimates rather than direct measurements.

The tool researchers often treat as a reference standard is the hyperinsulinemic-euglycemic clamp. In this laboratory procedure, insulin is infused to hold blood insulin at a steady raised level while glucose is infused at whatever rate keeps blood glucose constant. The amount of glucose that has to be supplied becomes a direct read-out of sensitivity: the more glucose the tissues take up at a fixed insulin level, the more sensitive they are understood to be. It is precise but labor-intensive, so it is used mainly in research rather than routine care.

These methods are described here to show how the concept is studied, not as instructions for self-assessment. Interpreting any glucose or insulin measurement — deciding what it means, whether further evaluation is warranted, and what if anything to do about it — is a clinical judgment that belongs to a licensed provider working with a full picture of an individual's health.

How prescription review works on OpenDoseRx

This guide describes biology, not treatment. Some prescription medications studied in the metabolic space are discussed in relation to insulin signaling — a companion guide on this hub describes how metformin is understood to work, for example — but nothing here recommends a product or suggests that any medication is right for a given person. Whether any medication is appropriate, and every detail of how it would be used, is a decision for an independent licensed provider. Where a product is a compounded preparation rather than an FDA-approved product, it is prepared by a licensed pharmacy for an individual prescription and is not itself FDA-approved.

On OpenDoseRx, that clinical decision rests with a licensed clinician, not the shopper. You begin by choosing a product and strength, then complete a medical intake that collects your health history and other relevant information. That intake is routed to an independent, licensed U.S. provider who reviews it. If the provider determines a prescription is appropriate, it is sent to a licensed U.S. pharmacy to be filled and shipped to you. If the request is declined, you are not charged for the medication and receive a full refund. Nothing here replaces a conversation with your own provider, and every product is dispensed only after that independent clinical review.